<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187132</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00049015</org_study_id>
    <nct_id>NCT03187132</nct_id>
  </id_info>
  <brief_title>Development and Validation of a Digital Pain-Reduction Kit for Musculoskeletal Injuries</brief_title>
  <official_title>Development and Validation of a Digital Pain-Reduction Kit for Musculoskeletal Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Travelers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AppliedVR Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hollywog, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effectiveness of an evidence-based, multi-modal, &quot;digital
      pain-reduction kit&quot; as a non-pharmacological supplement to managing patients with pain due to
      musculoskeletal injuries. Outpatients will be randomized to receive either the pain reduction
      kit or active control. The kit will contain a virtual reality (VR) headset, therapeutic VR
      visualization software, and a low-cost wearable transcutaneous electrical nerve stimulation
      (TENS) unit. Clinical staff will monitor progress and provide scheduled coaching and outreach
      to patients in the intervention group. The control group will receive the low-cost wearable
      transcutaneous electrical nerve stimulation (TENS) unit alone; they will not receive VR or
      remote coaching. Study devices will be delivered to the patient's home with instructions for
      use; patients will receive remote clinical and technical support. Patients will be followed
      for 60 days and monitored for functional status, pain levels, use of pain medications
      (including opioids), satisfaction with care, and time to returning to work.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Actual">May 20, 2020</completion_date>
  <primary_completion_date type="Actual">May 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Function</measure>
    <time_frame>60 days</time_frame>
    <description>Participants will complete weekly surveys (PROMIS® PF short-form) of self-reported physical function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Interference</measure>
    <time_frame>60 days</time_frame>
    <description>Participants will complete weekly surveys (PROMIS® Pain Interference) of self-reported pain interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity</measure>
    <time_frame>60 days</time_frame>
    <description>Participants will complete the WPAI:LB assessing work absenteeism and presenteeism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with Pain Treatment and Healthcare</measure>
    <time_frame>60 days</time_frame>
    <description>Investigators will assess satisfaction with healthcare in participants using a validated instruments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Use</measure>
    <time_frame>60 days</time_frame>
    <description>Investigators will examine pre and post prescription history for opioids using 90 Morphine Milligram Equivalents.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Pain, Acute</condition>
  <condition>Pain, Chronic</condition>
  <arm_group>
    <arm_group_label>Digital Pain Reduction Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Digital Pain Reduction Kit</intervention_name>
    <description>A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain.</description>
    <arm_group_label>Digital Pain Reduction Kit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Control</intervention_name>
    <description>An active control TENS unit used to reduce acute localized pain.</description>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Male or female, age 18 or older

          4. Seeking care for a musculoskeletal injury

          5. Experiencing pain greater than 3 out of 10 on a visual analog scale

          6. English or Spanish speaking

          7. Owns a compatible Android or iOS smartphone device (excluding tablets)

        Exclusion Criteria:

          1. Unable to understand the goals of the study due to cognitive difficulty

          2. Use of a cardiac pacemaker, implanted defibrillator, or other implanted metallic or
             electronic device or high-frequency surgical equipment. (contraindication for TENS
             units)

          3. Pregnant (contraindication for TENS unit)

          4. Current diagnosis of epilepsy, dementia, or other neurological disease that may
             prevent use of VR hardware or software

          5. Hypersensitivity to flashing light or motion

          6. Injury to the eyes, face, neck, or arms that prevents comfortable use of VR hardware
             or software, or safe use of other study hardware (e.g., open sores, wounds, or skin
             rash on face)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>July 18, 2020</last_update_submitted>
  <last_update_submitted_qc>July 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Brennan Spiegel</investigator_full_name>
    <investigator_title>Director, Health Services Research</investigator_title>
  </responsible_party>
  <keyword>virtual reality</keyword>
  <keyword>transcutaneous electrical nerve stimulation</keyword>
  <keyword>analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

